公开(公告)号：US4932458A

公开(公告)日：1990-06-12

申请号：US301153

申请日：1989-01-25

申请人： Norihiro Iwamoto ,  Hiroyuki Tsuboi ,  Toshihiko Kaneko

发明人： Norihiro Iwamoto ,  Hiroyuki Tsuboi ,  Toshihiko Kaneko

IPC分类号： B22D17/32 ,  B22D18/02 ,  B22D27/11

CPC分类号： B22D27/11 ,  B22D17/32

摘要： A method of and a system for operating a squeeze plunger in a die cast machine. When the fill-up of molten metal in a cavity is completed by an injection plunger, the moving speed of the injection plunger is rapidly decreased. When the speed at this time becomes lower than a preset value, a preset delay time is measured. After a lapse of this delay time, the squeeze plunger is operated to press a molding material in the cavity, so that plastic flows are caused in the molding material.

摘要翻译： 一种用于在压铸机中操作挤压柱塞的方法和系统。 当通过注射柱塞完成空腔中的熔融金属填充时，注射柱塞的移动速度快速降低。 当此时的速度低于预设值时，测量预设的延迟时间。 在经过该延迟时间之后，挤压柱塞被操作以将空腔中的模制材料挤压，从而在模制材料中引起塑性流动。

公开(公告)号：US5022457A

公开(公告)日：1991-06-11

申请号：US303236

申请日：1989-01-30

申请人： Norihiro Iwamoto ,  Hiroyuki Tsuboi ,  Toshihiko Kaneko

发明人： Norihiro Iwamoto ,  Hiroyuki Tsuboi ,  Toshihiko Kaneko

IPC分类号： B22D17/32

CPC分类号： B22D17/32

摘要： This invention relates to a casting control system of a die cast machine, and more particularly to a system for controlling a high speed injection real stroke of an injection plunger and controlling valve closing timing for degassing gas in a mold cavity. The high speed injection real stroke is measured by an arithmetic unit from a signal output from a position detector, and the high speed injection real stroke is then compared with a certain preset value. When arithmetic unit determines that the high speed injection real stroke and the preset value do not coincide with each other, a pretest action delay time of the injection plunger is .+-. incrementally or decrementally corrected until both values coincide. The arithmetic unit determines a start position of the high speed injection real stroke, outputs a signal to close a breathing valve at a position, to which is added or from which is subtracted a predetermined variable value with respect to the real start position and outputs a signal to open the breathing valve at a position where the injection plunger closes a molten metal feeding port.

摘要翻译： 压铸机的铸造控制系统技术领域本发明涉及一种压铸机的铸造控制系统，更具体地说，涉及一种用于控制喷射柱塞的高速喷射实际行程的系统，并且控制关闭模具腔中的气体的关闭正时。 通过来自位置检测器的信号的运算单元测量高速喷射实际行程，然后将高速喷射实际行程与某个预设值进行比较。 当运算单元确定高速喷射实际行程和预设值不一致时，注射柱塞的预测试动作延迟时间是+/-递增或递减校正直到两个值相符。 算术单元确定高速喷射实际行程的开始位置，输出一个关闭呼吸阀的信号，该位置被添加或相对于实际开始位置减去预定变量值，并输出一个 信号以在注射柱塞关闭熔融金属进料口的位置处打开呼吸阀。

公开(公告)号：US5207267A

公开(公告)日：1993-05-04

申请号：US743253

申请日：1991-08-09

申请人： Norihiro Iwamoto ,  Masayuki Takamura ,  Toshihiko Kaneko

发明人： Norihiro Iwamoto ,  Masayuki Takamura ,  Toshihiko Kaneko

IPC分类号： B22D17/32

CPC分类号： B22D17/32

摘要： A stroke-end position of an injection cylinder of the die cast machine is detected and a position of the injection cylinder for sending a boosting-signal is set. This position is a predetermined standard boost stroke distance from the stroke-end position. When the injection cylinder reaches the position for sending the boosting-signal in the casting cycle, an oil-pressure intensifier is advanced. In this method, before casting is performed, a value representing a stroke after slowing-down and a setting value of the plunger stopping position are determined and the start point for slowing-down is calculated by subtracting the value of the stroke after slowing down from the setting value.

摘要翻译： 检测压铸机的注射缸的行程终点位置，并设定用于发送升压信号的注射缸的位置。 该位置是从行程终点位置起预定的标准提升行程距离。 当注射缸到达用于在铸造循环中发送升压信号的位置时，油压增压器前进。 在该方法中，在进行铸造之前，确定表示减速后的行程和柱塞停止位置的设定值的值，并且通过从减速之后减去冲程值来计算减速起始点 设定值。

公开(公告)号：US09453000B2

公开(公告)日：2016-09-27

申请号：US12671873

申请日：2008-08-28

申请人： Teiji Kimura ,  Noritaka Kitazawa ,  Toshihiko Kaneko ,  Nobuaki Sato ,  Koki Kawano ,  Koichi Ito ,  Mamoru Takaishi ,  Takeo Sasaki ,  Yu Yoshida ,  Toshiyuki Uemura ,  Takashi Doko ,  Daisuke Shinmyo ,  Daiju Hasegawa ,  Takehiko Miyagawa ,  Hiroaki Hagiwara

发明人： Teiji Kimura ,  Noritaka Kitazawa ,  Toshihiko Kaneko ,  Nobuaki Sato ,  Koki Kawano ,  Koichi Ito ,  Mamoru Takaishi ,  Takeo Sasaki ,  Yu Yoshida ,  Toshiyuki Uemura ,  Takashi Doko ,  Daisuke Shinmyo ,  Daiju Hasegawa ,  Takehiko Miyagawa ,  Hiroaki Hagiwara

IPC分类号： C07D471/04 ,  A61K31/437 ,  C07D487/04 ,  C07D498/04 ,  C07D403/10 ,  A61P25/28 ,  C07D403/04

CPC分类号： C07D403/10 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04

摘要： Disclosed is a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, which is effective as a therapeutic or prophylactic agent for a disease induced by Aβ, wherein Ar1 represents an imidazolyl group which may be substituted with a C1-6 alkyl group, or the like; Ar2 represents a phenyl group which may be substituted with a C1-6 alkoxy group, or the like; X1 represents a double bond, or the like; and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, or the like.

公开(公告)号：US08456800B2

公开(公告)日：2013-06-04

申请号：US13190033

申请日：2011-07-25

申请人： Toshihiko Kaneko ,  Ryutaro Yamazaki ,  Taisuke Masuko ,  Yusuke Sato ,  Yasushi Matsuyama ,  Yasuo Watanabe ,  Masakazu Hosono ,  Saori Takeda ,  Hirobumi Tanaka ,  Makoto Endo

发明人： Toshihiko Kaneko ,  Ryutaro Yamazaki ,  Taisuke Masuko ,  Yusuke Sato ,  Yasushi Matsuyama ,  Yasuo Watanabe ,  Masakazu Hosono ,  Saori Takeda ,  Hirobumi Tanaka ,  Makoto Endo

IPC分类号： H01G4/06 ,  H01G4/005

CPC分类号： H01G4/1227 ,  C04B35/4682 ,  C04B2235/3206 ,  C04B2235/3224 ,  C04B2235/3225 ,  C04B2235/3262 ,  C04B2235/3418 ,  C04B2235/5409 ,  C04B2235/6025 ,  C04B2235/6582 ,  C04B2235/6584 ,  C04B2235/663 ,  C04B2235/80 ,  C04B2235/81 ,  H01G4/30

摘要： A multilayer ceramic electronic component comprises an element body obtained by stacking dielectric layers (thickness t1) and electrode layers (thickness t2). The dielectric layer includes a compound expressed by ABO3 (A includes Ba, and may include Ca or Sr; and B includes Ti, and may include Zr or Hf), and includes 0.75 to 2.0 moles of MgO, 0.4 to 1.0 mole of an oxide of Y, Dy, Ho and the like in terms of the oxide, and 0.4 to 0.8 mole of SiO2 per 100 moles of the compound. A segregation phase containing Mg is formed in at least a part of an electrode missing portion. Line coverage of the electrode layer is 60 to 90% and relations of 0.3 μm≦t1≦2.0 and 0.3 μm≦t2

摘要翻译： 多层陶瓷电子部件包括通过堆叠电介质层（厚度t1）和电极层（厚度t2）而获得的元件体。 电介质层包括由ABO 3表示的化合物（A包括Ba，并且可以包括Ca或Sr;并且B包括Ti，并且可以包括Zr或Hf），并且包括0.75至2.0摩尔的MgO，0.4至1.0摩尔的氧化物 的Y，Dy，Ho等，以及每100摩尔化合物为0.4〜0.8摩尔的SiO 2。 在电极缺失部分的至少一部分中形成含有Mg的偏析相。 电极层的线覆盖率为60〜90％，满足t1 = 2.0〜0.3μm，t2 <1.0μm的0.3μm的关系。

公开(公告)号：US20120094984A1

公开(公告)日：2012-04-19

申请号：US13333238

申请日：2011-12-21

申请人： Yuichi Suzuki ,  Takafumi Motoki ,  Toshihiko Kaneko ,  Mamoru Takaishi ,  Tasuku Ishida ,  Kunitoshi Takeda ,  Yoichi Kita ,  Noboru Yamamoto ,  Afzal Khan ,  Paschalis Dimopoulos

发明人： Yuichi Suzuki ,  Takafumi Motoki ,  Toshihiko Kaneko ,  Mamoru Takaishi ,  Tasuku Ishida ,  Kunitoshi Takeda ,  Yoichi Kita ,  Noboru Yamamoto ,  Afzal Khan ,  Paschalis Dimopoulos

IPC分类号： A61K31/5415 ,  A61P25/28 ,  C07D279/08 ,  C07D471/04 ,  C07D417/12 ,  C07D513/04

CPC分类号： A61K31/542 ,  C07D279/08 ,  C07D417/10 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D513/04

摘要： A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

摘要翻译： 由通式表示的化合物或其药学上可接受的盐或其溶剂化物，其中环A是C 6-14芳基等，L是-NReCO-等（其中Re是氢原子或 环）B是C 6-14芳基等，X是C 1-3亚烷基等，Y是单键等，Z是C 1-3亚烷基等，R 1 和R 2各自独立地为氢原子等，R 3，R 4，R 5和R 6独立地为氢原子，卤素原子等，具有A＆bgr; 产生抑制作用或BACE1抑制作用，可用作由A＆Bgr引起的神经变性疾病的预防或治疗剂; 并以阿尔茨海默氏型痴呆为代表。

公开(公告)号：US08048878B2

公开(公告)日：2011-11-01

申请号：US12403565

申请日：2009-03-13

申请人： Teiji Kimura ,  Koki Kawano ,  Eriko Doi ,  Noritaka Kitazawa ,  Mamoru Takaishi ,  Koichi Ito ,  Toshihiko Kaneko ,  Takeo Sasaki ,  Takehiko Miyagawa ,  Hiroaki Hagiwara ,  Yu Yoshida

发明人： Teiji Kimura ,  Koki Kawano ,  Eriko Doi ,  Noritaka Kitazawa ,  Mamoru Takaishi ,  Koichi Ito ,  Toshihiko Kaneko ,  Takeo Sasaki ,  Takehiko Miyagawa ,  Hiroaki Hagiwara ,  Yu Yoshida

IPC分类号： C07D491/02 ,  C07D265/36 ,  C07D498/02 ,  C07D295/00 ,  A61K31/535 ,  A61K31/50 ,  A61K31/44 ,  A01N43/60

CPC分类号： C07D471/04 ,  C07D487/04

摘要： The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R1 and R2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.

摘要翻译： 本发明涉及一种新型的两种环状肉桂酰胺化合物和包含该化合物作为活性成分的药剂。 由通式（I）表示的两个环状肉桂酰胺化合物：其中表示单键或双键; Ar 1表示可被1〜3个取代基取代的苯基或吡啶基; R1和R2各自表示C1-6烷基，羟基等; Z1表示亚甲基或亚乙烯基，其可以被1或2个选自取代基组A1，氧原子或可被选自取代基组A1的取代基取代的亚氨基取代基取代; p，q和r各自表示0〜2的整数，其具有降低A＆bgr 40和A＆bgr 42生成的效果，因此特别可用作由A＆bgr引起的神经变性疾病的预防或治疗剂。 如阿尔茨海默病或唐氏综合症。

公开(公告)号：US08008293B2

公开(公告)日：2011-08-30

申请号：US12522281

申请日：2008-02-27

申请人： Teiji Kimura ,  Koki Kawano ,  Eriko Doi ,  Noritaka Kitazawa ,  Mamoru Takaishi ,  Koichi Ito ,  Toshihiko Kaneko ,  Takeo Sasaki ,  Nobuaki Sato ,  Takehiko Miyagawa ,  Hiroaki Hagiwara

发明人： Teiji Kimura ,  Koki Kawano ,  Eriko Doi ,  Noritaka Kitazawa ,  Mamoru Takaishi ,  Koichi Ito ,  Toshihiko Kaneko ,  Takeo Sasaki ,  Nobuaki Sato ,  Takehiko Miyagawa ,  Hiroaki Hagiwara

IPC分类号： C07D498/04 ,  A61K31/5375

CPC分类号： C07D498/04

摘要： The present invention relates to a compound represented by formula (I): wherein R1 represents a C1-3 alkyl group, R2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.

摘要翻译： 本发明涉及由式（I）表示的化合物：其中R1表示C1-3烷基，R2表示氢原子或C1-3烷基，Ar表示可被基团取代的苯基等 1〜3个取代基，X表示氧原子等，n和m相同或不同，为0〜2的整数，或药理学上可接受的盐及其作为药物的用途。

公开(公告)号：US07973033B2

公开(公告)日：2011-07-05

申请号：US13005064

申请日：2011-01-12

申请人： Teiji Kimura ,  Noritaka Kitazawa ,  Toshihiko Kaneko ,  Nobuaki Sato ,  Koki Kawano ,  Koichi Ito ,  Eriko Doi ,  Mamoru Takaishi ,  Takeo Sasaki ,  Takehiko Miyagawa ,  Hiroaki Hagiwara ,  Takashi Doko

发明人： Teiji Kimura ,  Noritaka Kitazawa ,  Toshihiko Kaneko ,  Nobuaki Sato ,  Koki Kawano ,  Koichi Ito ,  Eriko Doi ,  Mamoru Takaishi ,  Takeo Sasaki ,  Takehiko Miyagawa ,  Hiroaki Hagiwara ,  Takashi Doko

IPC分类号： C07D471/04 ,  C07D498/04 ,  A61K31/5383 ,  A61K31/5025

CPC分类号： C07D403/10 ,  C07D471/04 ,  C07D498/04

摘要： The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

公开(公告)号：US20100317850A1

公开(公告)日：2010-12-16

申请号：US12863364

申请日：2009-01-16

申请人： Yuichi Suzuki ,  Takafumi Motoki ,  Toshihiko Kaneko ,  Mamoru Takaishi ,  Tasuku Ishida ,  Kunitoshi Takeda ,  Yoichi Kita ,  Noboru Yamamoto ,  Afzal Khan ,  Paschalis Dimopoulos

发明人： Yuichi Suzuki ,  Takafumi Motoki ,  Toshihiko Kaneko ,  Mamoru Takaishi ,  Tasuku Ishida ,  Kunitoshi Takeda ,  Yoichi Kita ,  Noboru Yamamoto ,  Afzal Khan ,  Paschalis Dimopoulos

IPC分类号： C07D513/04 ,  C07D417/12

CPC分类号： A61K31/542 ,  C07D279/08 ,  C07D417/10 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D513/04

摘要： Disclosed is a compound represented by General formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt, which has an inhibitory activity of the production of Aβ or a BACE1-inhibiting activity, and is therefore useful as a prophylactic or therapeutic agent for Aβ-induced neurodegenerative diseases typified by Alzheimer-type dementia. Wherein the ring A represents a C6-14 aryl group or the like; L represents —NReCO— [wherein Re represents a hydrogen atom or the like] or the like; the ring B represents a C6-14 aryl group or the like; X represents a C1-3 alkylene group or the like; Y represents a single bond or the like; Z represents a C1-3 alkylene group or the like; R1 and R2 independently represent a hydrogen atom or the like; and R3, R4, R5 and R6 independently represent a hydrogen atom, a halogen atom or the like.

摘要翻译： 公开了通式（I）表示的化合物或其药学上可接受的盐，或该化合物或其药学上可接受的盐的溶剂化物，其具有抑制A＆Bgr生产的活性; 或BACE1抑制活性，因此可用作用于以阿尔茨海默氏型痴呆为代表的引起神经退行性疾病的预防或治疗剂。 其中环A表示C6-14芳基等; L表示-NReCO- [其中Re表示氢原子等]等; 环B表示C 6-14芳基等; X表示C1-3亚烷基等; Y表示单键等; Z表示C1-3亚烷基等; R1和R2独立地表示氢原子等; R 3，R 4，R 5和R 6独立地表示氢原子，卤素原子等。